Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Revisiting Opioid Use Disorder (July/August/September) | 2023

View Archived Issues

Learning Objectives, Revisiting Opioid Use Disorder, CATR, Jul/Aug/Sept 2023

May 29, 2023

After reading these articles, you should be able to…

Fentanyl Testing: An Emerging Harm Reduction Strategy

May 29, 2023

Noah Capurso, MD and Alyssa Falleni, PharmD

Discover the lifesaving potential of fentanyl test strips (FTS). As fentanyl infiltrates illicit drug markets, FTS offer an essential harm reduction strategy. We’ll explore the technology behind FTS, how to obtain and use them, discuss their legality, and examine their role in preventing opioid overdose deaths.

The State of Opioids on the Street

May 29, 2023

Daniel Ciccarone, MD, MPH

Dr. Ciccarone sheds light on the current chaotic and perilous situation surrounding illicit opioids found on the streets.

Starting Medication for Opioid Use Disorder

May 29, 2023

Gretchen Hermes, MD, PhD

Dr. Hermes discusses the intricacies of medications for opioid use disorder by outlining the advantages, disadvantages, and side effect profile of each. She will help you choose the best treatment approach for your patients with opioid use disorder by providing a review of relevant literature and gives you language to use in the clinic.

What Psychiatrists Need to Know About Intravenous Drug Use and Endocarditis

May 29, 2023

Kenechukwu Mezue, MD, MSc and Bernardo Lombo, MD, FACC

Infective endocarditis (IE) is a dangerous and potentially life-threatening complication of intravenous drug use. This article explores the pathogenesis of IE, key symptoms to recognize, and the crucial steps to take if an infection is suspected.

Intravenous Buprenorphine Microinduction

May 29, 2023

Noah Capurso, MD and Marissa Bayerl, APRN

Buprenorphine microinduction can be a useful method of starting BUP induction, however it is not always feasible, particularly in the hospital setting. Here, we discuss the development of an intravenous microinduction protocol that could provide an alternative to the usual sublingual and transdermal routes of administration.